动脉网获悉,2025年6月9日,在药明生物成都微生物商业化生产基地启动活动上,专注于内分泌相关治疗领域的创新型生物医药公司维升药业(2561.HK)与药明生物(2269.HK)宣布了一项重要的合作进展:维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都。此外,双方还将在该基地合作建设国内首条双腔冻干制剂生产线,这一创新型药物制剂生产技术能极大地提升药物稳定性及使用便利性。值得一提的是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.